NICE guidelines on anti-tumor necrosis factor therapy for RA

Nature Clinical Practice Rheumatology

Volumn 5, Issue 1, 2009, Pages 16-17

  Scott, David L ^a   Steer, Sophia ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; B LYMPHOCYTE ANTIBODY; CD4+ T LYMPHOCYTE COSTIMULATION MODULATOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; JOINTS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58049215333     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0964     Document Type: Article

References (16)

1. Rawlins MD and Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329: 224-227
2. Maynard A et al. (2004) Challenges for the National Institute for Clinical Excellence. BMJ 329: 227-229
3. National Institute for Health and Clinical Excellence [www.nice.org.uk/ Guidance/TA130/Guidance/pdf/English] (accessed 6 November 2008)
4. Chen YF et al. (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10: 1-229
5. Zink A et al. (2006) Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54: 3399-3407
6. Greenberg JD et al. (2008) Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 121: 532-538
7. Goekoop-Ruiterman YP et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 52: 3381-3390
8. van Vollenhoven RF (2004) Switching between biological agents. Clin Exp Rheumatol 22 (5 Suppl 35): S115-S121
9. Keystone EC (2006) Switching tumor necrosis factor inhibitors: An opinion. Nat Clin Pract Rheumatol 2: 576-577
10. Erickson AR and Mikuls TR (2007) Switching anti-TNF-alpha agents: What is the evidence? Curr Rheumatol Rep 9: 416-420
11. Bombardieri S et al. (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46: 1191-1199
12. Buch MH et al. (2007) Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthritis Rheum 57: 448-453
13. Hyrich KL et al. (2008) Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 47: 1000-1005
14. Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 56: 13-20
15. Karlsson JA et al. (2008) Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47: 507-513
16. Barton P et al. (2004) The use of modelling to evaluate new drugs for patients with a chronic condition: The case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 8: Iii, 1-91